Spark Therapeutics, Inc. entered into an Agreement and Plan of Merger, dated as of February 22, 2019, with Roche Holdings, Inc., and 022019 Merger Subsidiary, Inc. At the Effective Time of the Merger, the following individuals resigned as members of the board of directors (or similar governing body) of Spark and its subsidiaries, and from all committees of the board of directors (or similar governing body) of Spark and its subsidiaries: Steven M. Altschuler, Lars G. Ekman, M.D., Ph.D., Katherine A. High, M.D., Jeffrey D. Marrazzo, Anand Mehra, M.D., Vincent J. Milano, Robert J. Perez, Elliott Sigal, M.D., Ph.D. and Lota Zoth, CPA. Effective immediately following the resignations described above, Bruce Resnick and Sean Johnston were appointed as the directors of Spark.